• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vertex Pharmaceuticals (NQ: VRTX )

    482.48 +1.24 (+0.26%)
    Streaming Delayed Price Updated: 11:36 AM EDT, Aug 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Vertex Pharmaceuticals

    < Previous 1 2
    ...
    5 6 7 8 9 10 11 12 13
    ...
    51 52 Next >
    Vertex Pharmaceuticals Is About to Extend Its Leadership in This Billion-Dollar Market
    Vertex's main business may be heading for a new era of growth... 
    Via The Motley Fool
    Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought
    These exciting players could deliver explosive growth over time. 
    Via The Motley Fool
    3 Revolutionary Biotech Stocks Poised for 10X Surge
    Discover three biotech stocks set to soar in a $3.08 trillion market, merging medical innovations with financial growth opportunities. 
    Via InvestorPlace
    3 Magnificent Growth Stocks to Buy Right Now
    These stocks share at least two common denominators: a biopharmaceutical focus and great long-term prospects. 
    Via The Motley Fool
    Could This News Upset Vertex Pharmaceuticals' Prospects in the Billion-Dollar Pain Management Market?
    The pain market is in great need of new options. 
    Via The Motley Fool
    2 Top Growth Stocks to Buy With $1,000 Right Now
    Even a modest starting investment in the right stocks could pay off in the years ahead. 
    Via The Motley Fool
    Stock-Split Watch: Is Vertex Pharmaceuticals Next?
    It's on track to launch more blockbuster drugs. 
    Via The Motley Fool
    Could Vertex Pharmaceuticals Reach $500 in 2024?
    Vertex shares have several catalysts on the horizon... 
    Via The Motley Fool
    Vertex Pharmaceuticals Stock Is Approaching a Huge Catalyst, But Is It a Buy?
    Its pain medicine isn't precisely what it hoped for, but it could still sell. 
    Via The Motley Fool
    Vertex Pharmaceuticals Will Use $100 Million to Tank Its Own Market Share. Here's Why That's a Smart Move.
    Sometimes, the winning move doesn't look right at first. 
    Via The Motley Fool
    2 Healthcare Growth Stocks That Are No-Brainer Buys Right Now
    The healthcare industry often remains resilient amid macro headwinds, and these two stocks are prime examples. 
    Via The Motley Fool
    Giving Uber Its Due
    We've also got a look at good news from Chipotle and Roblox, and we put some stocks on a dating show. 
    Via The Motley Fool
    Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade.
    These stocks have what it takes to drive superior returns in the years to come. 
    Via The Motley Fool
    Gene therapy: Why does it cost millions for a single treatment?
    Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. 
    Via MarketBeat
    Exposures Product Safety
    $100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
    Via Benzinga
    Is Vertex Pharmaceuticals Stock Too Expensive With a Price-to-Sales Ratio of 11x?
    There's more to consider with Vertex's valuation than one number. 
    Via The Motley Fool
    If You Invested $10,000 in Vertex Pharmaceuticals in 2014, This Is How Much You Would Have Today
    You can't go back in the past, but it's not too late to invest in this top stock. 
    Via The Motley Fool
    European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    2 Healthcare Stocks That Could Help Set You Up for Life
    These rock-solid businesses can add meaningful returns to a long-term portfolio. 
    Via The Motley Fool
    3 Groundbreaking Healthcare Stocks to Buy for Robust Gains
    Get the latest investment advice for healthcare stocks in 2024. Discover top picks and growth opportunities for the healthcare sector. 
    Via InvestorPlace
    Is Vertex Pharmaceuticals Stock a Buy Now?
    The company just released its latest earnings report, and growth investors may be a little disappointed. 
    Via The Motley Fool
    2 Healthcare Stocks You Can Buy and Hold for the Next Decade
    These businesses are built to last. 
    Via The Motley Fool
    2 No-Brainer Healthcare Stocks to Buy Right Now
    Companies in the healthcare industry tend to generate returns in a wide range of market environments. 
    Via The Motley Fool
    3 Stocks That Could Trounce the Market in 2024
    These stocks appear to have what it takes to beat the market this year. 
    Via The Motley Fool
    3 Growth Stocks With More Potential Than Any Cryptocurrency
    The stock market is full of opportunities for investors of all risk appetites and trading styles. 
    Via The Motley Fool
    3 Strong Buy Healthcare Stocks to Add to Your February Must-Watch List
    These strong buy healthcare stocks are among analysts' favorite picks, and their strong market position tells us why. 
    Via InvestorPlace
    Stock Market Hits Highs As AI Plays Arm, Palantir Skyrocket: Weekly Review
    The S&P 500 hit 5,000. Arm, Palantir and Cloudflare rose sharply. 
    Via Investor's Business Daily
    Topics Artificial Intelligence Stocks
    Exposures Artificial Intelligence US Equities
    Vertex's Next-Generation Cystic Fibrosis Program Shows Efficacy With Reduced Burden, Provides Growth Opportunity: Goldman Sachs
    Vertex Pharmaceuticals' cystic fibrosis treatment with vanza triple therapy. SKYLINE trials show non-inferiority to Trikafta, emphasizing once-daily dosing benefits. 
    Via Benzinga
    Vertex Pharmaceuticals' Triple Combo Treatment For Lung Disorder Meets Primary Goal In Adult And Pediatric Patients
    Vertex Pharmaceuticals' vanza triple program for cystic fibrosis, with superior results in lung function, sweat chloride reduction, and safety. 
    Via Benzinga
    Vertex Pharmaceuticals Has a $10 Billion Opportunity on the Table. Here's How You Can Invest
    Its foray into developing analgesics seems to be going swimmingly. 
    Via The Motley Fool
    < Previous 1 2
    ...
    5 6 7 8 9 10 11 12 13
    ...
    51 52 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.